Laboratory of Ultrastructure, Aggeu Magalhães Institute (IAM), Recife, Brazil.
Postgraduate Program in Biosciences and Biotechnology for Health (PPGBBS), Oswaldo Cruz Foundation (FIOCRUZ-PE)/Aggeu Magalhães Institute (IAM), Recife, Brazil.
Front Immunol. 2022 Jul 28;13:946698. doi: 10.3389/fimmu.2022.946698. eCollection 2022.
Multiple sclerosis (MS) is a highly disabling, progressive neurodegenerative disease with no curative treatment available. Although significant progress has been made in understanding how MS develops, there remain aspects of disease pathogenesis that are yet to be fully elucidated. In this regard, studies have shown that dysfunctional adenosinergic signaling plays a pivotal role, as patients with MS have altered levels adenosine (ADO), adenosine receptors and proteins involved in the generation and termination of ADO signaling, such as CD39 and adenosine deaminase (ADA). We have therefore performed a literature review regarding the involvement of the adenosinergic system in the development of MS and propose mechanisms by which the modulation of this system can support drug development and repurposing.
多发性硬化症（MS）是一种高度致残、进行性神经退行性疾病，目前尚无治愈方法。尽管在了解 MS 如何发展方面取得了重大进展，但疾病发病机制的某些方面仍未完全阐明。在这方面，研究表明，功能失调的腺苷能信号传导起着关键作用，因为 MS 患者的腺苷（ADO）、腺苷受体和参与 ADO 信号产生和终止的蛋白（如 CD39 和腺苷脱氨酶（ADA））水平发生改变。因此，我们对腺苷能系统在 MS 发展中的作用进行了文献综述，并提出了通过调节该系统来支持药物开发和重新定位的机制。
